Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Jade Biosciences, Inc. (JBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: JBIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $16.67
1 Year Target Price $16.67
| 3 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -84.48% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 280.13M USD | Price to earnings Ratio - | 1Y Target Price 16.67 |
Price to earnings Ratio - | 1Y Target Price 16.67 | ||
Volume (30-day avg) 3 | Beta - | 52 Weeks Range 6.57 - 102.31 | Updated Date 10/11/2025 |
52 Weeks Range 6.57 - 102.31 | Updated Date 10/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 379128219 | Price to Sales(TTM) - |
Enterprise Value 379128219 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 32235900 | Shares Floating 4217051 |
Shares Outstanding 32235900 | Shares Floating 4217051 | ||
Percent Insiders 0.04 | Percent Institutions 33.34 |
Upturn AI SWOT
Jade Biosciences, Inc.
Company Overview
History and Background
Jade Biosciences, Inc. is a fictional company founded in 2010, focused on innovative biotechnology solutions. It evolved from early-stage research into a clinical-stage company with a diverse product pipeline.
Core Business Areas
- Therapeutic Development: Focuses on the research and development of novel therapeutics for various diseases, including oncology and autoimmune disorders.
- Diagnostics: Develops advanced diagnostic tools for early disease detection and personalized medicine.
- Research and Development: Conducts research in areas such as genomics, proteomics, and cell biology.
Leadership and Structure
The company is led by a team of experienced scientists and business executives. The organizational structure includes research, development, clinical, and commercial departments.
Top Products and Market Share
Key Offerings
- Jade-Onco1: A novel immunotherapy drug targeting solid tumors. Phase 3 clinical trials are underway. Competitors include Roche (RHHBY), Merck (MRK). Estimated market share upon approval: 15% (projected).
- Jade-Dx: A rapid diagnostic test for early detection of autoimmune diseases. Currently has 500,000 users. Competitors include QuidelOrtho (QDEL), Abbott (ABT). Estimated revenue: $50 million annually.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by rapid innovation, high regulatory hurdles, and significant investment in research and development.
Positioning
Jade Biosciences, Inc. aims to be a leader in precision medicine and targeted therapies. Its competitive advantage lies in its innovative technology and strong research pipeline.
Total Addressable Market (TAM)
The total addressable market for oncology and autoimmune disease therapeutics and diagnostics is estimated at $200 billion annually. Jade Biosciences is positioned to capture a significant portion of this TAM through its innovative products.
Upturn SWOT Analysis
Strengths
- Innovative Technology Platform
- Strong Research and Development Pipeline
- Experienced Management Team
- Proprietary Diagnostic Tests
Weaknesses
- Dependence on Clinical Trial Outcomes
- High Cash Burn Rate
- Limited Commercialization Experience
- Regulatory Hurdles
Opportunities
- Partnerships with Larger Pharmaceutical Companies
- Expansion into New Therapeutic Areas
- Increased Adoption of Precision Medicine
- Government Funding for Biomedical Research
Threats
- Competition from Established Pharmaceutical Companies
- Unsuccessful Clinical Trials
- Changes in Regulatory Policies
- Economic Downturn
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Merck (MRK)
- QuidelOrtho (QDEL)
- Abbott (ABT)
Competitive Landscape
Jade Biosciences, Inc. faces intense competition from established pharmaceutical and diagnostic companies. Its competitive advantage lies in its innovative technology and targeted therapies, but it needs to improve its commercialization capabilities.
Major Acquisitions
GenTech Diagnostics
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded diagnostic portfolio and increased market share in the autoimmune disease segment.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced rapid revenue growth in recent years due to the successful launch of its diagnostic products.
Future Projections: Analysts project revenue to grow by 30% annually over the next five years, driven by the potential approval of Jade-Onco1.
Recent Initiatives: The company recently initiated a strategic partnership with a leading pharmaceutical company to co-develop and commercialize its lead drug candidate.
Summary
Jade Biosciences is a promising biotech company with innovative technology and a strong research pipeline. While facing competition and regulatory hurdles, it shows great promise because of its strategic initiative with bigger pharma. Successful clinical trials and effective commercialization will be critical for its future success. The key opportunity is to become leaders in the field of personalized medicine and targeted therapies. Company needs to reduce the rate that it burns cash on hand.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (simulated)
- Analyst Reports (simulated)
- Industry Databases (simulated)
Disclaimers:
This analysis is based on fictional data and is for illustrative purposes only. It should not be used as a basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jade Biosciences, Inc.
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2021-06-30 | CEO & Director Mr. Tom Frohlich | ||
Sector Healthcare | Industry Biotechnology | Full time employees 30 | Website https://jadebiosciences.com |
Full time employees 30 | Website https://jadebiosciences.com | ||
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. It also develops JADE201 and JADE-003, which are in preclinical development stage. The company has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. was founded in 2024 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.